Dr Reddy’s Laboratories (DRL), an integrated global pharmaceutical company, has launched decitabine for injection (50mg) a therapeutic equivalent generic version of Dacogen (decitabine for injection) in the US market, following the approval by the United States Food & Drug Administration (FDA) of Dr Reddy’s ANDA for decitabine for injection.

The Dacogen brand has US sales of approximately $260 million MAT for the most recent twelve months ending in July 2013 according to IMS Health.

Dr Reddy’s decitabine for injection 50 mg is available as a single dose vial.

Dr Reddy’s Laboratories is committed to providing affordable and innovative medicines for healthier lives.